The present invention provides a method of diagnosis and/or discrimination of prostate cancer in a patient, comprising the steps of: - determining the content of ITIH4 fragment peptide in urine taken from the body of the patient, and - determining the content of ITIH4 fragment peptide in serum taken from the body of the patient, and/or determining the content of ITIL fragment peptide 1 and/or ITIL fragment peptide 2 in urine taken from the body of the patient, - calculating at least one of: - serum:urinary ITIH4 peptide fragment index, being the ratio of the content of ITIH4 fragment peptide in serum and the content of ITIH4 in urine, and - urinary ITIH4:ITIL peptide fragment index, being the ratio of the content of ITIH4 in urine and the content of ITIL fragment peptide 1 and/or ITIL fragment peptide 2 in urine, - comparing said one or both peptide fragment indexes with the indexes of healthy controls and/or individuals suffering from benign prostatic hyperplasia (BPH), wherein: - when the ratio of the content of ITIH4 fragment peptide in serum to the content of ITIH4 in urine is lower than said ratio of the healthy control and/or individuals suffering from BPH, then prostate cancer is diagnosed in said patient, and/or - when the ratio of the content of ITIH4 in urine to the content of ITIL fragment peptide 1 and/or ITIL fragment peptide 2 in urine is higher than said ratio of the healthy control and/or individuals suffering from BPH, then prostate cancer is diagnosed in said patient.